Protein aggregate myopathies (PAMs) define muscle disorders characterized by protein accumulation in muscle fibres. We describe a new PAM in a patient with proximal muscle weakness and hypertrophic cardiomyopathy, whose muscle fibres contained inclusions containing myosin and myosin-associated proteins, and aberrant distribution of microtubules. These lesions appear as intact A-and M-bands lacking thin filaments and Z-discs. These features differ from inclusions in myosin storage myopathy (MSM), but are highly similar to those in mice deficient for the muscle-specific RING finger proteins MuRF1 and MuRF3. Sanger sequencing excluded mutations in the MSM-associated gene MYH7 but identified mutations in TRIM63 and TRIM54, encoding MuRF1 and MuRF3, respectively. No mutations in other potentially disease-causing genes were identified by Sanger and whole exome sequencing. Analysis of seven family members revealed that both mutations segregated in the family but only the homozygous TRIM63 null mutation in combination with the heterozygous TRIM54 mutation found in the proband caused the disease phenotype. Both MuRFs are microtubule-associated proteins localizing to sarcomeric M-bands and Z-discs. They are E3 ubiquitin ligases that play a role in degradation of sarcomeric proteins, stabilization of microtubules and myogenesis. Lack of ubiquitin and the 20S proteasome subunit in the inclusions found in the patient suggested impaired turnover of thick filament proteins. Disruption of microtubules in cultured myotubes was rescued by transient expression of wild-type MuRF1. The unique features of this novel myopathy point to defects in homeostasis of A-band proteins in combination with instability of microtubules as cause of the disease. † These authors contributed equally to this work.
Introduction
Protein aggregate myopathies (PAMs) are a group of inherited or acquired muscle disorders characterized morphologically by abnormal accumulation of proteins within muscle fibres (1). These clinically and genetically diverse conditions are classified on the basis of the morphology and composition of protein aggregates observed as inclusions in muscle cells, and ultimately on the identification of causative gene. With only some exceptions, inherited PAMs are caused by mutations in cytoskeletal and sarcomeric proteins. Myofibrillar myopathies (MFMs) (2) , actinopathy (3) and myosin storage myopathy (MSM) (4), among many others, are well-known examples of PAMs.
The MFMs, the largest group of PAMs, are characterized by a common pattern of dissolution of myofibrils that begins at the Z-disc and is followed by the accumulation of the products of myofibrillar degradation into inclusions containing desmin and multiple other proteins. Immunohistochemical and proteomic studies have demonstrated Z-disc proteins as the most abundantly expressed in aggregates in MFM, whereas myosin and myosin-associated proteins are typically diminished or absent (1, 2, (5) (6) (7) . MFMs have been associated with mutations in DES, CRYAB, MYOT, ZASP, FLNC, BAG3, FHL1 and TTN genes (8) .
Actinopathy, caused by mutations in ACTA1, is a severe congenital myopathy defined by selective accumulation of actin filaments usually localized at the periphery of muscle fibres and appearing as areas devoid of ATPase and oxidative enzyme activities in the light microscope (3) .
The MSM, another well-known PAM, is characterized by subsarcolemmal accumulation of unstructured non-membranebound material (hyaline bodies) in type I fibres (9) . The hyaline bodies lack oxidative enzyme activity but display ATPase activity, indicating that they contain myosin. This is further demonstrated by immunohistochemical analysis showing slow/β-cardiac myosin heavy chain (MyHC), as the major component of the accumulated material. Ultrastructurally, the hyaline bodies appear as granular material usually well demarcated from surrounding, intact myofibrils.
So far, mutations located in exons 37-40 of MYH7 encoding the distal end of the tail of slow/β-cardiac MyHC are the only identified genetic cause of MSM (9) . However, a disease reminiscent of MSM has been described in mice with simultaneous inactivation of the TRIM63 and TRIM54 genes encoding the muscle-specific RING finger (MuRF) proteins MuRF1 and MuRF3, respectively (10) . Both MuRFs are striated muscle-specific E3 ubiquitin ligases involved in regulation of sarcomeric protein degradation (11, 12) . They are also essential for linking myofibril components with microtubules, intermediate filaments and nuclear factors (13) . Double knockout mice for MuRF1 and MuRF3 develop cardiomyopathy and skeletal myopathy pathologically characterized by aggregates of partly fragmented sarcomeres with preserved A-and M-bands (10) .
We have identified a patient suffering from hypertrophic cardiomyopathy (HCM) and skeletal myopathy with morphological features identical to those described for MuRF1 −/−
/MuRF3
−/− mice in addition to abnormal topology and distribution of microtubules. The patient was homozygous for a null mutation in TRIM63 and heterozygous for a deleterious missense mutation in TRIM54. Analysis of additional members of the family revealed that both mutations segregated in the family, but in line with the double knockout mouse model, only the combination of the homozygous TRIM63 and heterozygous TRIM54 mutations was associated with severe cardiomyopathy and skeletal myopathy. Here we report the clinical, pathological and genetic characterization of a novel and unique PAM associated with combined TRIM63 and TRIM54 mutations.
Results

Clinical findings
The proband (III:4) (Fig. 1A) , a 60-year-old man, first complained of dyspnoea upon exertion at the age of 15. Five years later, he was diagnosed with HCM based on ECG findings. His clinical condition remained fairly static until the fourth decade when he developed a slowly progressing weakness in proximal muscles of four limbs manifested with difficulties on stairs or lifting heavy objects. A first echocardiogram at 55 years revealed a non-obstructive HCM. A year later, after an episode of palpitations, an atrial flutter was diagnosed. He was treated with diltiazem 200 mg daily because he did not tolerate betablockers owing to asthenia. The patient had no story of hypertension.
The patient's older half-sister (III:1) (Fig. 1A) suffered from muscle weakness and cardiac disease and died from heart failure at the age of 46 years. At the age of 75 years, individual III:3 has been diagnosed with cardiac hypertrophy thought to be secondary to chronic hypertension. Clinical and echocardiographic evaluation of six asymptomatic family members (Supplementary Material, Tables S2 and S3) revealed neither muscle weakness nor signs of cardiac failure.
Clinical examination of the proband (III:4) revealed generalized loss of subcutaneous fatty tissue, rigidity of the spine, hypertrophy of deltoids, biceps and calf muscles, and scapular winging (Fig. 1B.i-iv) . The facial and extraocular muscles were intact. He had symmetrical muscle weakness involving pectoralis, deltoids, biceps and humeral rotators (MRC 4). In the lower extremities there was weakness of hip abductors (MRC 4), iliopsoas (MRC 3), knee flexors and extensors and less prominent weakness of the anterior tibialis muscles (MRC 4). He was unable to get up from the floor or stand up from a chair without support, and had a waddling gait. Deep tendon reflexes were hypoactive; sensation was intact. His blood pressure was 110/70 mmHg. Laboratory investigations revealed 2-to 6-fold-increased serum CK levels, and a NT-proBNP value of 1219 ng/l (normal <300). EMG examination was consistent with a myopathy. A muscle MRI (Fig. 1C .i-iv) showed generalized loss of subcutaneous adipose tissue and severe fatty replacement of lumbar paraspinal muscles, the glutei as well as the anterior and posterior muscles of the thigh. The rectus femoris, sartorius, gracilis and, to a lesser extent, the semitendinosus were well preserved and appeared hypertrophic. At the mid-leg level, the soleus was the most severely affected.
The ECG showed signs of enlarged left atrium, a PR of 160 ms, and a QRS of 100 ms with q waves in the lateral leads. Twentyfour hour Holter monitoring revealed episodes of atrial arrhythmia and premature ventricular beats. Echocardiography showed a non-dilated left ventricle with global hypertrophy, especially of the septum, with global hypokinesia, a reduced ejection fraction of 41%, and irreversible restrictive filling (Supplementary Material, Table S3 ). The right ventricle was hypertrophic with good systolic function. There was biatrial dilatation, more on the left. Cardiac MRI showed extensive and diffuse areas of late gadolinium enhancement in the left ventricle with a subepicardic and mesocardic pattern, preserving the sub-endocardium (Fig. 1D.i and ii). This extensive and diffuse myocardial fibrosis that corresponds with the akinetic and hypokinetic segments seen in the gradient echo cine images suggests an infiltrative-restrictive cardiomyopathy. Respiratory function tests revealed a forced vital capacity (FVC) of 2.77 l (66% of predicted) standing, and 2.33 l Human Molecular Genetics, 2015, Vol. 24, No. 13 | 3639 Histological, immunohistochemical, immunofluorescence and ultrastructural analysis of skeletal muscle Muscle biopsy from the proband (III:4) showed increased variability in fibre size, with some atrophic fibres and mild endomysial fibrosis. The most conspicuous finding was the presence of single or multiple well-circumscribed non-membrane-bound subsarcolemmal deposits in the majority of type I fibres. They were faintly basophilic on HE staining, stained light green with modified trichrome and were negative with PAS, ORO and Congo red staining. The nuclei were hypertrophic and were frequently found at the periphery or even within the inclusions ( Fig. 2A and B) . Most of the deposits were devoid of mitochondrial oxidative enzyme activity as revealed by SDH and COX but were often surrounded by a rim of enhanced oxidative activity ( Fig. 2A , B and D). In addition, central fibre regions showed uneven distribution of oxidative enzyme activity (Fig. 2D) . ATPase activity at pH 4.35 was preserved within inclusions and revealed type I fibre predominance. Immunolabeling revealed accumulation of slow MyHC (Figs 2C, 3A and C.i), MuRF3 ( Fig. 3B and C .ii), M-protein and myomesin ( Fig. 3D and E) within the inclusions but absence of desmin (Fig. 2E) , myotilin, actin and other Z-disc-associated proteins (data not shown). The subsarcolemmal inclusions With the modified trichrome (B) the inclusions stained light green (arrows). Immunohistochemical analysis (C) revealed strong slow MyHC immunoreactivity in fibre regions containing inclusions (arrows). Succinate dehydrogenase (D) shows reduced oxidative enzyme activity surrounded by a rim of increased activity in some fibres (arrows), whereas enhanced oxidative enzyme activity is seen in others (double arrows). Note uneven distribution of oxidative enzyme activity in central fibre regions (asterisks) and absence of desmin (E) and ubiquitin (F) immunoreactivity in fibre regions containing inclusions.
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were not ubiquitinated (Fig. 2F ). Double immunolabeling revealed partial co-localization of MyHC and MuRF3 (Fig. 3C .i-iii). Ultrastructural analysis identified the inclusions as characteristic, aberrantly oriented sarcomere fragments with preserved Aand M-bands but lacking I-bands and Z-discs ( Fig. 4A and B) . These abnormal fibre regions varied in length and width, and were observed under the sarcolemma or dispersed between normal myofibrils. Groups of mitochondria were often found at the periphery of sarcomere fragments or intermingled with them. In addition, there were areas with Z-disc streaming and myofibrillar disorganization, extending from two to several sarcomeres on longitudinal sections (Fig. 4C ). Some autophagic vacuoles were observed within areas of myofibrillar disorganization (Fig. 4D ).
Genetic findings
The patient was initially tested for mutations in MYH7, the only gene known to be involved in MSM (4) and no mutations were found. He was subsequently tested for a panel of potential candidate genes including a panel of genes involved in familial HCM. As no mutations were found and given the striking similarities of the pathological features observed in the muscle of our patient with those found in the MuRF1 −/− /MuRF3 −/− mice, the patient was subsequently screened for mutations in TRIM63 and TRIM54. Sanger sequencing of TRIM63 and TRIM54 identified two mutations in the proband (III:4) (Fig. 1A) : a homozygous nonsense mutation, c.739C>T (CAG>TAG), in exon 5 of TRIM63, changing the glutamine at position 247 to a stop codon ( p.Gln247Ter), and a heterozygous missense mutation, c.316G>A (GAC>AAC), in and the two children (IV:1 and IV:2) were heterozygous and one sibling (III:3) was homozygous for the TRIM63 mutation. In addition to the proband, two family members (III:7 and IV:2) were heterozygous for the TRIM54 mutation. The p.Asp106Asn mutation is located in the MuRF family conserved domain (MFC), which is conserved in all MuRF isogenes (Supplementary Material, Fig. S1D ). The RFLP and sequence analyses excluded the TRIM63 and TRIM54 sequence variants in 400 control chromosomes. However, both mutations were observed as rare variants in the Exome Variant Server (National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP), Seattle, WA, USA; http ://evs.gs.washington.edu/EVS/), which contains data from over 5000 individuals. Heterozygous variant of TRIM63 p.Gln247Ter appeared in the European American (A = 6/G = 8594 allele) but not in the African American population (A = 0/G = 4406 allele). There was no homozygous variant of TRIM63 p.Gln247Ter in this population (AA = 0/AG = 6/GG = 4294). In addition, the heterozygous variant of TRIM54 p.Asp106Asn appeared only in the European American (A = 6/G = 8594 allele, AA = 0/AG = 6/GG = 4294), but not the African American population (A = 0/G = 4406 allele). Furthermore, the combined TRIM63 p.Gln247Ter and TRIM54 p.Asp106Asn variants was not identified in the data from 5000 individuals in the Exome Variant Server.
Finally, in order to exclude any other potential disease-causing gene mutations, we performed whole-exome sequencing (WES) on the proband. WES identified 49 266 variants (14 262 genes). Application of filtering strategy reduced the starting variants to nine variants (nine genes). These variants were identified in the Exome Aggregation Consortium (ExAC) Browser (Beta) (Supplementary Material, Table S4 ). Among these genes, only TRIM63 and TRIM54 encode striated muscle-specific proteins. Thus, the results further demonstrated that the combined homozygous TRIM63 and heterozygous TRIM54 mutations were the cause of the disease.
The RT-PCR analysis indicated complete absence of TRIM63 transcripts in the proband (Fig. 5) , suggesting nonsense-mediated mRNA decay, whereas expression of both alleles of TRIM54 was found in muscle tissue and cultured cells of the proband (Fig. 5  and Supplementary Material, Fig. S1B and C) . Human
Protein expression in muscle tissue and cultured myoblasts
Immunofluorescence and confocal microscope analysis further confirmed subsarcolemmal accumulation of MyHC in the muscle fibres of the proband (III:4) (Fig. 3A and C.i) . In addition, immunoblot analyses revealed increased expression of MyHC when compared with healthy controls (Fig. 6A ) and the absence of full-size or truncated MuRF1 protein (Fig. 6A) . Considering that MyHC is highly degraded in critically ill ICU patients (14) , and that MuRF1 is an E3 ubiquitin ligase that mediates ubiquitination of MyHC for degradation by the UPS, we predicted that the expression of MuRF1 should be up-regulated in these patients. Indeed, we detected an increased expression level of MuRF1 in a critically ill ICU patient associated with markedly reduced MyHC expression (Fig. 6A) , suggesting the involvement of MuRF1 in thick filament degradation. Immunofluorescence and western blot analyses showed subsarcolemmal accumulation and increased expression levels of MuRF3 in the index patient (Figs 3B, C.ii and 6B), which may suggest that also degradation of MuRF3 is compromised.
To further evaluate the consequences of the MuRF1 and MuRF3 mutations on the turnover of thick filament proteins, we analysed the expression of ubiquitin linked at Lys48 or Lys63 residues and the 20S proteasome subunit in the protein deposits. No ubiquitin linked at Lys48 or Lys63 residues (Fig. 7A.i-iii) or proteasome 20S subunit (Fig. 7B.i ) expression was observed in the subsarcolemmal inclusions, whereas strong staining of the cytoplasmic inclusions was observed in a patient with myofibrillar myopathy resulting from a MYOT mutation, that was processed in parallel and used as a positive control (Fig. 7A.iv-vi, B .ii).
MuRF3 is required for establishment of a stable microtubule network in striated muscle (13) . In order to determine whether microtubule organization was affected, we stained cultured myoblasts and skeletal muscle fibres of the patient for α-tubulin. While control myoblasts showed a well-organized microtubule network, patient myoblasts showed diffuse and punctate α-tubulin distribution (Fig. 8, arrows) . Similarly, while the control muscle specimen showed evenly organized microtubules, we found aberrant α-tubulin distribution at the periphery of the patient muscle fibres (Fig. 8, arrows) . Together, this indicates a severe disruption of the microtubule network in skeletal muscle fibres and cultured myoblasts of the patient. Double immunolabeling of α-tubulin and MyHC revealed distribution of α-tubulin mainly at the periphery of MyHC accumulations (data not shown).
Co-staining of normal cultured human myocytes with antibodies to MuRF1 or MuRF3 and α-tubulin, indicated that both MuRFs are tightly associated with linearly aligned microtubules (Supplementary Material, Fig. S2A and B) . In addition, MuRF1 and MuRF3 strictly co-localized in human myocytes (Supplementary Material, Fig. S2C, insets) . This suggests that in human striated muscle, both MuRF1 and 3 play an instrumental role in the regulation of microtubule stability, either individually or via heterodimerization.
Rescue of the phenotype by transfection with WT-MuRF1 EGFP
Consistent with the data from immunoblot analyses, immunolocalization studies of myoblasts from the index patient showed lack of MuRF1 (Fig. 9A) . Staining of cells with DAPI revealed bigger nuclei in patient myoblasts, which were often irregular and lobular in morphology compared with control cells (Fig. 9A and  Supplementary Material, Fig. S3 ). The average maximum diameter of the patient's myoblast nuclei was 29.90 ± 1.31 µm (s.e.), whereas the average maximum diameter of control cell nuclei was 21.15 ± 0.43 µm (s.e.). Transient expression of wild-type MuRF1 EGFP fusion protein in patient myocytes rescued this phenotype: cells showed reformation of microtubule networks and normal nuclear morphology and size (average maximum diameter 15.52 ± 1.31 µm (s.e.)), indicating that the absence of MuRF1 in patient cells was responsible for the phenotype (Fig. 9B and C) . Indeed, similar to endogenous MuRF1 in control myoblasts, transfected WT-MuRF1 EGFP was found in close association with microtubules (Fig. 9C , insets and Supplementary Material, Fig. S2A, insets) .
These experiments not only indicate that the expression of MuRF1 is sufficient to rescue the phenotype but also that the endogenous heterozygous MuRF3 missense mutation alone is not sufficiently pathogenic to cause abnormal distribution of microtubules.
Discussion
This paper describes a novel PAM and cardiomyopathy resulting from combined homozygous MuRF1 null mutation and heterozygous MuRF3 missense mutation. Skeletal muscle biopsy of the index patient revealed unique pathological features characterized by subsarcolemmal protein deposits containing myosin and myosin-associated proteins, while being devoid of thin-filament-and Z-disc-associated proteins. By electron microscopy abnormal fibre regions contained sarcomere fragments with intact thick filaments and M-bands, but lacking or diminished Z-discs and I-bands as most characteristic and frequent finding. According to these features this new entity should be classified as a new member of the PAMs. Although the deposition of slow myosin is reminiscent of MSM (4, 15) , no mutations in MYH7 were found in our family. Moreover, the ultrastructural features observed in the skeletal muscle fibres of our patient are unique and sharply different from the non-structured granular material corresponding to the hyaline bodies observed in MSM. To our knowledge, the features described above have never been observed before in human myopathies. However, they are highly similar to those described in MuRF1
Mice deficient in MuRF1 or MuRF3 do not display obvious phenotypes (16) (17) (18) . In contrast, inactivation of MuRF1 and MuRF3 in mice results in cardiomyopathy and skeletal myopathy (10) . Affected muscle fibres of MuRF1 −/− /MuRF3 −/− mice show accumulation of partly fragmented sarcomeres with preserved A-and M-bands, suggesting a role of MuRF1 and MuRF3 in the turnover of thick filament proteins (10) . In contrast, absence of Z-disc components in these aggregates suggests that degradation of Z-disc proteins is independent of MuRF1 and MuRF3 (10). The highly similar morphological alterations in the muscle of our patient prompted us to consider TRIM63 and TRIM54 as plausible disease-causing genes. In accordance with features found in the MuRF1 
/MuRF2
−/− mice, a feature postulated to be related to an increased protein anabolism (19) . This can be explained by the possible association of MuRF with transcriptional regulation and energy metabolism (20) . The association of muscle weakness, muscle hypertrophy, cardiomyopathy and rigid spine observed in the proband (III:4) has some similarities to the clinical phenotype observed in patients carrying mutations in distal exons of FHL1, presenting with X-linked myopathy and postural atrophy and generalized hypertrophy (XMPMA) (21) or Emery Dreyfuss muscular dystrophy (EDMD) (22) . However, genetic analysis of FHL1 did not reveal any mutations. Mutations in other potentially candidate genes were also excluded.
The skeletal and cardiac muscle hypertrophy in the index patient is consistent with the known role of MuRF1 as regulator of muscle mass in striated muscles (16, 17, 23, 24) . MuRF1 is required to prevent cardiac hypertrophy and its expression is up-regulated in mouse models with skeletal and cardiac muscle atrophy (16, 17, 23) . Endomyocardial biopsy was not performed, but echocardiography and MRI examinations revealed restrictive cardiomyopathy. As in MuRF1 −/−
/MuRF3
−/− mice, accumulations of thick filaments were also observed in cardiomyocytes (10) , it is very likely that in our patient the cardiac phenotype is also associated with-or even caused by-deposition of thick filaments. Individual III:3 carrying the homozygous TRIM63 null mutation, but not the heterozygous TRIM54 missense mutation was diagnosed with HCM secondary to chronic hypertension. Whether the homozygous TRIM63 null mutation contributes to cardiac hypertrophy in this individual remains unclear and deserves further investigations.
It has been suggested that heterozygous TRIM63 p.Gln247Ter variant is associated with human HCM (25) . The pathogenicity of this variant was demonstrated by a number of functional studies (25) . However, clinical investigation of four family members (III:6, III:7, IV:1 and IV:2) carrying the heterozygous TRIM63 null mutation ( p.Gln247Ter) did not reveal any sign of skeletal myopathy or cardiomyopathy, indicating that the hemizygous loss of TRIM63 is well tolerated. This is further supported by the recent identification of this heterozygous TRIM63 null variant in a family with two individuals without HCM (26) . Furthermore, a higher prevalence of rare TRIM63 and TRIM55 heterozygous variants has been recently reported in HCM patients with pathogenic sarcomere mutations than in control subjects. It was suggested that the presence of these variants at heterozygous state might modify the phenotypic expression of HCM rather than causing the disease (27) . Moreover, the heterozygous p.Gln247Ter TRIM63 mutation appears as a rare variant in the Exome Variant Server. Together, this indicates that neither the heterozygous p. Gln247Ter TRIM63 mutation alone nor the combined heterozygous mutations in TRIM63 and TRIM54 is sufficient to cause HCM.
Sarcomeres are dynamic structures, in which damaged proteins are exchanged continuously (28) . The ubiquitin-proteasomal system (UPS) is pivotal for the selective degradation or recycling of cytoplasmic and nuclear proteins (29) . Substrate recognition for ubiquitination is highly specific and provided by the E3 ubiquitin ligases allowing its transport to the 26S proteasome complex (29, 30) . MuRF1 and MuRF3 are E3 ubiquitin ligases that specifically mediate the degradation of MyHCs via the UPS in striated muscles (10, 31) . The selective accumulation of thick filaments in our patient, that were neither ubiquitinated, nor labelled with antibodies against the 20S proteasome subunit, suggests a specific impairment of their degradation owing to complete MuRF1-deficiency and a deleterious MuRF3 missense mutation. Noteworthy is that also MuRF1 −/−
−/− mice demonstrate impaired ubiquitination of slow MyHC (10). In our patient (III:4), the single functional MuRF3 allele alone is obviously not sufficient to mediate ubiquitination and subsequent proteasomal degradation of thick filament proteins. Besides the impaired thick filament degradation as a result of defective E3 ubiquitin ligase activities, this study indicates that perturbation of the microtubule network is an important factor contributing to the pathogenesis of this new entity. MuRF1 and MuRF3 are required for microtubule stability and play a major role during myogenesis (11, 13, 18, 31, 32) . Previous studies have shown that thick filaments assemble independently (33, 34) and that microtubules stabilize and position these filaments prior to their incorporation into mature sarcomeres (35) . In the family analysed here, neither the heterozygous MuRF3 missense mutation nor the heterozygous MuRF1 null mutation alone was associated with cardiomyopathy or skeletal myopathy. However, the combination of MuRF1-deficiency with mutant MuRF3 leads to impaired organization of the microtubule network, associated with a misarrangement of myosin-containing filaments within sarcomeres, resulting in the unique accumulation of 'free-floating A-bands' devoid of thin-filament-and Z-disc proteins.
Transient expression of wild-type MuRF1 in myoblasts of our index patient, rescued the formation of a microtubule network, while WT-MuRF1 EGFP was incorporated into microtubules similarly to endogenous MuRF1 in control myoblasts. These results indicate that the establishment of a microtubule network in myoblasts is dependent on its association with MuRF1, which in turn acts as a transient scaffold for myofibril assembly. The phenotype of giant, irregular and lobular nuclei with a number of nucleoli is consistent with a defect in the modulation of microtubule Human Molecular Genetics, 2015, Vol. 24, No. 13 | 3647 dynamics and has been observed in both centromere protein C gene (Cenpc) disrupted mice and inner centromere protein (Incenp) gene disrupted mice (36, 37) . Interestingly, myoblasts from the index patient with transient expression of wild-type MuRF1 showed normal nuclear morphology and size, further indicating the essential role of MuRF1 in the modulation of microtubule structure.
In conclusion, we describe a novel human disease characterized by HCM and progressive skeletal myopathy caused by a combination of complete MuRF1-deficiency and a deleterious MuRF3 missense mutation. Our observations suggest that MuRF1 and MuRF3 not only functionally cooperate in the regulation of proteasomal degradation of thick filament proteins but also orchestrate the positioning of thick filaments within the sarcomeres by stabilizing microtubules.
Patients and Methods
Patient identification and evaluation
Eight individuals from a four-generation Spanish family (Fig. 1) were studied after obtaining informed consent according to the guidelines of the Ethics Committee of the Hospital Universitari de Bellvitge. The following investigations were conducted in the index patient: pedigree analysis, neurologic examination including muscle strength evaluation according to the Medical Research Council (MRC) grading scale, serum CK and NT-proBNP levels, electromyography, cardiologic examination with electrocardiography (ECG), 24-h Holter monitoring, echocardiography and cardiac MRI, respiratory function tests, and muscle MRI at lower lumbar, pelvic, mid-thigh and mid-lower-leg levels. Seven additional family members were clinically examined, and in three of them (individuals III:3, III:7 and IV:2) an echocardiography was performed
Analyses of muscle biopsy and tissue culture
An open muscle biopsy specimen was obtained from the biceps brachii of the index patient (III:4) after obtaining informed consent. Myoblasts were isolated and cultured as previously described (38) . Morphological and histochemical analyses of fresh frozen muscle tissue were performed according to standard protocols. Sections of skeletal muscle and cultured cells were processed for immunohistochemical, immunofluorescence and immunoblot assessments. Detailed methods are provided in the Supplementary Material, Appendix.
Molecular genetics
Genetic analysis Genomic DNA was extracted from blood using DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). The proband ( patient III.4) was initially screened for mutations in MYH7 and several other genes encoding sarcomeric proteins. The entire coding region and exon-intron boundaries of MYH7, ACTA1, TPM2, TPM3, TNNT1, ACTN3, ACTN2 and FHL1 were analysed. A panel of genes involved in familial HCM, including MYBPC3, TNNT2, TNNI3, TPM1, MYL2, ACTC1, MYL3, CSRP3, TTN, TCAP, TNNC1 and MYH6 (39, 40) were also analysed. The entire coding region and exon-intron boundaries of TRIM63 and TRIM54 were analysed by polymerase chain reaction (PCR) and direct sequencing. Primer sequences for amplification of analysed genes are available on request. DNA samples isolated from 100 Swedish and 100 Spanish blood donors served as controls. The appearance of the nonsense TRIM63 mutation was evaluated by sequencing TRIM63 exon 5 in the family members and in the 400 control chromosomes. Loss of a Taq α I restriction enzyme site was used to confirm the TRIM54 mutation c.316G>A (GAC>AAC), ( p.Asp106Asn) in patient and family members and in 200 control individuals by digesting a TRIM54 exon 2 PCR product with Taq α I. The following primer pair was used to amplify exon 2: 5′-CCTCCTCC GAGTCCCTTC-3′ and 5′-CTCTGATGGGTTCCTTGGC-3′. Furthermore, WES was performed on blood DNA from the proband. Data from WES were analysed using Ingenuity ® Variant
Analysis™ software (www.qiagen.com/ingenuity) from QIAGEN (Redwood City, CA, USA). Only those changes that were predicted to be damaging or with unknown impact were kept. We excluded SNPs that were shared with our control dataset (>1% in dpSNP, the Exome Variant Server (NHLBI), the 1000 Genome Project Database and the human Background Variant DataBase (http://neotek .scilifelab.se/hbvdb/)). Reverse-transcriptase (RT)-PCR was used to assay the expression of TRIM63 and TRIM54. Detailed methods are provided in the Supplementary Material, Appendix.
Generation of cell culture models
A construct of wild-type (WT-) MuRF1 EGFP was generated by amplifying MuRF1 cDNA obtained by reverse transcription of RNA from a normal skeletal muscle specimen. Cells were transfected using Lipofectamine 2000™ (Invitrogen Life Technologies, Carlsbad, CA, USA; (3)) and fixed and stained for immunofluorescence. Detailed methods are provided in the Supplementary Material, Appendix.
